HAEK HAEMATO AG

EQS-News: HAEMATO AG: Dividend of EUR 1.20

EQS-News: HAEMATO AG / Key word(s): Dividend
HAEMATO AG: Dividend of EUR 1.20

16.05.2023 / 17:40 CET/CEST
The issuer is solely responsible for the content of this announcement.

Dividend of EUR 1.20

 Berlin, May 16, 2023 - At today's balance sheet meeting, the annual financial statements 2022 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.20 per dividend-bearing share to the Annual General Meeting taking place in presence on July 18th 2023.

About HAEMATO:

HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced specialty pharmaceutical drugs (with a therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at .

.Contact:

HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70

16.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail:
Internet:
ISIN: DE000A289VV1
WKN: A289VV
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1634693

 
End of News EQS News Service

1634693  16.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1634693&application_name=news&site_id=research_pool
EN
16/05/2023

Underlying

HAEKHAEMATO AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HAEMATO AG

Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann
HAEK HAEMATO AG

Research Note - HAEMATO AG - 15.12.2023

Die HAEMATO AG ist ein börsennotiertes Unternehmen mit Fokus auf den Bereichen Specialty-Pharma und Lifestyle & Aesthetics. Die Geschäftsaktivitäten konzentrieren sich auf Wachstumsmärkte patentfreier und patentgeschützter Arzneimittel. Schwerpunkte bilden die Therapiebereiche Onkologie, HIV/AIDS, Neu-rologie, Herz-Kreislauf- und andere chronische Erkrankungen. Im schnell wachsenden Markt der ästheti-schen Medizin fokussiert sich die HAEMATO AG auf den größten Markt für Privatzahler. Der Bedarf ...

12/15/23 December 15, 2023 5 DE
Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann
HAEK HAEMATO AG

Research Note english - HAEMATO AG - 15.12.2023

HAEMATO AG is a listed company with a focus on the specialty pharma and lifestyle & aesthetics sectors. Their business activities are concentrated on growth markets for off-patent and patent-protected drugs. Their main focus is on the therapeutic areas of oncology, HIV/AIDS, neurology, cardiovascular and other chronic diseases. In the fast-growing market of aesthetic medicine, HAEMATO AG focuses on the largest market for private payers. The need for affordable medicines that are delivered at the...

12/15/23 December 15, 2023 5 EN
 PRESS RELEASE
Free
HAEK HAEMATO AG

EQS-News: HAEMATO AG veröffentlicht Zahlen für das dritte Quartal 2023...

EQS-News: HAEMATO AG / Schlagwort(e): Quartalsergebnis/9-Monatszahlen HAEMATO AG veröffentlicht Zahlen für das dritte Quartal 2023: Umsatzsteigerung von rund 13 % im Vergleich zum Vorjahreszeitraum, starke Erhöhung der EBIT-Marge und signifikante Steigerung des operati 16.11.2023 / 08:21 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. HAEMATO AG veröffentlicht Zahlen für das dritte Quartal 2023: Umsatzsteigerung von rund 13 % im Vergleich zum Vorjahreszeitraum, starke Erhöhung der EBIT-Marge und signifikante Steigerung des operativen...

November 16, 2023 1 DE
 PRESS RELEASE
Free
HAEK HAEMATO AG

EQS-News: HAEMATO AG publishes figures for the third quarter of 2023: ...

EQS-News: HAEMATO AG / Key word(s): Quarter Results/9 Month figures HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in 16.11.2023 / 08:21 CET/CEST The issuer is solely responsible for the content of this announcement. HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in operating re...

November 16, 2023 1 EN
Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann
HAEK HAEMATO AG

Research Note englisch - HAEMATO AG - 14.09.2023

HAEMATO AG is a listed company with a focus on the specialty pharma and lifestyle & aesthetics sectors. Their business activities are concentrated on growth markets for off-patent and patent-protected drugs. Their main focus is on the therapeutic areas of oncology, HIV/AIDS, neurology, cardiovascular and other chronic diseases. In the fast-growing market of aesthetic medicine, HAEMATO AG focuses on the largest market for private payers. The need for affordable medicines that are delivered at the...

09/14/23 September 14, 2023 9 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch